Welcome to the e-CCO Library!

P447: Seasonal variations in Vitamin D concentrations in a single-centre inflammatory bowel disease series
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Vernia*, G. Burrelli Scotti, M. T. Afferri, V. Vaiarello

Created: Friday, 22 February 2019, 9:49 AM
P447: The impact of therapeutic drug monitoring during biosimilar infliximab switch in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Ranjan*1, S. Myers2, L. Crissop1, S. Ritchie1, F. Maw1, S. Sebastian2, A. Dhar1

Created: Friday, 22 February 2019, 9:41 AM
P447: Vedolizumab induces significantly higher endoscopic remission rates at week 16 in ulcerative colitis as compared to Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Pauwels R.W.M., De Vries A.C., Van der Woude C.J.

Created: Wednesday, 20 February 2019, 10:36 AM
P448 Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extension
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Danese1, R. Panaccione2, L. Peyrin-Biroulet3, C. Marano4, C.D. O’Brien4, H. Zhang5, Y. Zhou5, J. Johanns5, E. Scherl6, R.W.L. Leong7, D.S. Rowbotham8, R.P. Arasaradnam9, B.E. Sands10

Created: Thursday, 30 January 2020, 10:12 AM
P448: Biologic therapy and immunodulators are associated with decreased risk of cardiovascular events in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Fumery M.*1, Singh A.2, Khera R.3, Prokop L.4, Curtis J.5, Sandborn W.6, Singh S.6

Created: Wednesday, 20 February 2019, 10:36 AM
P448: Cannabis and cannabinoids for the treatment of inflammatory bowel disease: a systematic review and meta-analysis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Doeve1, F. van Schaik*1, M. van de Meeberg1, H. Fidder1

Created: Friday, 22 February 2019, 9:41 AM
P448: IBD nurse in patients’ health status assessment: data from a pilot study comparing ability of IBD nurse and gastroenterologist in using IBD clinical scores
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

F. Mocciaro*1, R. Di Mitri1, G. M. Pecoraro1, D. Scimeca2, G. Russo1, F. Bossa2, V. Costanza1, D. Varvara2, M. A. Profita1, G. Profeta1, G. Martino2

Created: Friday, 22 February 2019, 9:49 AM
P448: Long term effectiveness of first-line infliximab treatment compared to conventional treatment in paediatric moderate-to-severe Crohn's disease – an update from the TISKids study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Vuijk, S.(1)*;Jongsma, M.(1);Cozijnsen, M.(1);van Pieterson, M.(1);de Meij, T.(2);Norbruis, O.(3);Groeneweg, M.(4);Wolters, V.(5);van Wering, H.(6);Hojsak, I.(7);Kolho, K.L.(8);Hummel, T.(9);Stapelbroek, J.(10);van der Feen, C.(11);van Rheenen, P.(12);van Wijk, M.(2);Teklenburg, S.(3);Escher, J.(1);de Ridder, L.(1);
Created: Friday, 14 July 2023, 11:05 AM
P448: Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
Year: 2022
Source: ECCO'22
Authors: Kim, K.(1);Hong, H.S.(1);Oh, K.(1);Lee, J.Y.(1);Hong, S.W.(1);Park, J.H.(1);Hwang, S.W.(1,2);Yang, D.H.(1);Byeon, J.S.(1);Ye, B.D.(1,2);Myung, S.J.(1);Yang, S.K.(1,2);Park, S.H.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
P448: Remission induction therapy with tacrolimus and biological combination therapy for severe ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Ito*

Created: Thursday, 21 February 2019, 9:14 AM
P448: Safety of anti-TNF introduction following tuberculosis treatment in Inflammatory Bowel Disease patients in an endemic area
Year: 2021
Source: ECCO'21 Virtual
Authors: Azevedo, M.F.C.D.(1);Justus, F.F.(1);Lima, C.C.G.(1);Garcia, K.S.(1);Barros, L.L.(1);Oba, J.(1);Carlos, A.D.S.(1);Milani, L.R.(1);Sipahi, A.M.(1);Damião, A.O.M.C.(1);Queiroz, N.S.F.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P449 Systematic review with meta-analysis: risk of lymphoma associated with anti-tumour necrosis factor (TNF) agents in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. CHUPIN1, V. Perduca2, C. Bellanger1, F. Carbonnel1, C. Dong1

Created: Thursday, 30 January 2020, 10:12 AM
P449: Autologous fat graft injection for the treatment of perianal fistulas in Crohn’s disease: A systematic review and single-arm meta-analysis
Year: 2022
Source: ECCO'22
Authors: De Gregorio, M.(1,2);Tiang, T.(3);Lee, T.(1);Stellingwerf, M.E.(4);Basnayake, C.(1,2);Kamm, M.A.(1,2);Niewiadomski, O.(1,5);Schulberg, J.D.(1,2);Wright, E.K.(1,2);Connell, W.(1);Thompson, A.J.(1,2);D'Souza co-lead senior author, B.(3,6);Ding, N.S.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
P449: Cost Effectiveness of a Proactive Therapeutic Drug Monitoring Strategy in Patients with Inflammatory Bowel Disease Receiving Infliximab
Year: 2021
Source: ECCO'21 Virtual
Authors: Doherty, J.(1);Varley, R.(1);Healy, M.(2);Dunne, C.(1);Mac Carthy, F.(1);Mc Kiernan, S.(1);Hartery, K.(1);Kevans, D.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P449: Double assessment of ileal pouch-anal anastomosis before ileostomy reversal
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Gklavas1*, G. Exarchos1, L. Metaxa2, G. Karamanolis1, I. Papaconstantinou1

Created: Thursday, 21 February 2019, 9:14 AM
P449: Efficacy and safety of switching between originator and biosimilar infliximab in patients with inflammatory bowel disease in practical clinic: results to 6 months
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

L. Díaz Hernández*1, G. E. Rodríguez González1, M. Vela González1, C. A. Tardillo Marín1, C. Y. Rodríguez Díaz1, L. Arranz Hernández1, J. A. Montero Delgado2, M. San Juan Acosta1, F. Pérez Hernández1

Created: Friday, 22 February 2019, 9:49 AM
P449: Minimally invasive IPAA in UC: Preliminary results from a referral center
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Fortuna, L.(1)*;Bottari, A.(1);Ficari, F.(1);Cricchio, M.(1);Cianchi, F.(1);Scaringi, S.(1);
Created: Friday, 14 July 2023, 11:05 AM
P449: Patient support program for adalimumab-treated patients with Crohn's disease in Brazil: impact on patients' adherence and persistence
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Teich V.*1, Arinelli R.1, Gulart A.1, Chaves L.2, Garg V.2, Skup M.2

Created: Wednesday, 20 February 2019, 10:36 AM
P449: Selective depletion of LAG3+ cells in T-cell-driven inflammation: a randomised, double-blind, placebo-controlled, FTIH phase I/Ib clinical trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Ellis1, D. Marks*1, C. Barrett1, T. Hopkins1, A. Richards1, R. Fuhr2, M. Albayaty3, M. Coenen4, L. Liefaard5, K. Leavens1, K. Nevin1, S. Tang6, S. Hughes1, N. Srinivasan1, K. Edwards5, R. Anselm5, T. Schmidt7, J. Stone8, C. Savage1, N. Wisniacki1, R. Tarzi1

Created: Friday, 22 February 2019, 9:41 AM
P450 Thioguanine and low dose thiopurines and allopurinol are both safe options after failure of conventional thiopurines: a comparative analysis of two multicentre cohorts
Year: 2020
Source:

ECCO'20 Vienna

Authors:

V. Biemans Drs1, E. Savelkoul2, G. Dijkstra3, M. Simsek4, R. Gabriels5, M. Pierik6, R. West7, N. de Boer8, F. Hoentjen2

Created: Thursday, 30 January 2020, 10:12 AM